Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
38 stopped studies mapped to Adult Acute Lymphoblastic Leukemia and descendants · 82% state a reason
Over the 38 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06570915 | Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy(T-ALL-2024) | Phase 2 | withdrawn | Aug 26, 2024 | Institute of Hematology & Blood Diseases Hospital, China | No eligeble patients | Other (stated, no rule matched) |
| NCT02333162 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in… | Phase 1 | suspended | Jan 7, 2015 | University of Chicago | Enrollment on hold pending amendment | Enrollment / accrual |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory… | Phase 1 / Phase 2 | terminated | Jul 29, 2019 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Phase 1 | terminated | Mar 21, 2019 | Cyclacel Pharmaceuticals, Inc. | Switch to oral formulation of CYC140 (plogosertib) | Other (stated, no rule matched) |
| NCT04554459 | Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult…(Pona-CELL) | Phase 2 | terminated | Sep 18, 2020 | Institute of Hematology and Blood Transfusion, Czech Republic | slower recruitment rate; | Enrollment / accrual |
| NCT04545333 | The clonoSEQ® Watch Registry | — | terminated | Sep 11, 2020 | Adaptive Biotechnologies | Sufficient data collected. | Other (stated, no rule matched) |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the… | Phase 1 / Phase 2 | withdrawn | Jun 8, 2023 | Indiana University | PI has left IU with no plan to initiate study at IU | Other (stated, no rule matched) |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell… | Phase 1 | terminated | Apr 7, 2017 | Fred Hutchinson Cancer Center | Terminated due to slow enrollment and end of funding | Enrollment / accrual |
| NCT03982992 | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab(DLI-TARGET) | Phase 2 | withdrawn | Jun 12, 2019 | Ludwig-Maximilians - University of Munich | Lack of potential study subjects due to a change of standard of care treatment outside of clinical… | Other (stated, no rule matched) |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT03705507 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of…(SeluDex) | Phase 1 / Phase 2 | terminated | Oct 15, 2018 | University of Birmingham | Poor recruitment, due to a change in the standard of care for this patient population with the use… | Enrollment / accrual |
| NCT05361356 | Spectral CT Clinical Trial | N/A | terminated | May 4, 2022 | Philips (China) Investment CO., LTD | Investigational product had been released in NMPA, Sponsor decided to terminate the study aligned… | Investigator |
| NCT00589316 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body… | Phase 1 | terminated | Jan 9, 2008 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT04044560 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant(OZM-097) | Phase 2 | terminated | Aug 5, 2019 | University of British Columbia | Slow enrolment, loss of funding | Enrollment / accrual |
| NCT02819804 | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia… | Phase 1 | terminated | Jun 30, 2016 | Northwestern University | Due to funding and accrual issues | Enrollment / accrual |
| NCT01408160 | Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Aug 3, 2011 | Albert Einstein College of Medicine | not stated | Not stated |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin… | Phase 2 | withdrawn | Sep 2, 2015 | University of Washington | Drugs unavailable | Other (stated, no rule matched) |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | Phase 2 | terminated | Mar 27, 2012 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT01383447 | Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory… | Phase 1 / Phase 2 | terminated | Jun 28, 2011 | National Cancer Institute (NCI) | This study was halted prematurely by the NCI for low accrual. | Enrollment / accrual |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT02129062 | Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic… | Phase 2 | terminated | May 2, 2014 | National Cancer Institute (NCI) | Slow accrual. | Enrollment / accrual |
| NCT02861040 | Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or… | Phase 1 | withdrawn | Aug 10, 2016 | Northwestern University | not stated | Not stated |
| NCT01401322 | Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic… | Phase 2 | terminated | Jul 25, 2011 | Stanford University | low accrual | Enrollment / accrual |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Nov 3, 2014 | Mayo Clinic | not stated | Not stated |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT01670084 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed… | Phase 2 | withdrawn | Aug 21, 2012 | Mayo Clinic | No Accrual | Enrollment / accrual |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT00262925 | Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory… | Phase 2 | terminated | Dec 7, 2005 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | Phase 2 | terminated | Oct 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00301769 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic… | Phase 1 | terminated | Mar 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101231 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With… | Phase 1 | terminated | Feb 8, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem… | N/A | withdrawn | Mar 20, 2012 | Roswell Park Cancer Institute | device not available | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 13, 2026source: clinicaltrials